


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001516551	Load Guard Logistics, Inc.	© Corporation
Name of Issuer	Load Guard	C Limited Partnership
Nemus Bioscience, Inc.	Transportation, Inc.	6
Jurisdiction of Incorporation/Organization	LOAD GUARD LOGISTICS, INC.	C General Partnership
NEVADA	LOAD GUARD TRANSPORTATION,	C Business Trust
	INC.	C Other
Year of Incorporation/Organiz	cation	
O Over Five Years Ago		
Within Last Five Years (Specify Year)	2011	
C Yet to Be Formed		





Last Name		First Name		Middle Name	
Berecz	Elizabeth			M.	
Street Address 1			J [
650 Town Center Drive			Suite 620		
City		State/Province/0	Country	ZIP/Postal Code	
Costa Mesa		CALIFORNIA	<u> </u>	92626	
Relationship:	Execut	ive Officer	Director	Promoter	
Clarification of Response (if Necessary)					
Last Name	Last Name First Name			Middle Name	
Murphy		Brian		S.	
Street Address 1			Street Address 2		
650 Town Center Driv	ve		Suite 620		
City		State/Province/0	Country	ZIP/Postal Code	
Costa Mesa		CALIFORNIA	<u> </u>	92626	
Relationship:	Execut	ive Officer	Director	Promoter	
Clarification of Response	(if Necessary	7)			
Last Name		First Name		Middle Name	
McLaughlin		Gerald		W.	
Street Address 1			Street Address 2		
650 Town Center Driv	ve		Suite 620		
City		State/Province/Country		ZIP/Postal Code	
Costa Mesa		CALIFORNIA		92626	
Relationship:	Execut	ive Officer	☑ Director	Promoter	
Clarification of Response	(if Necessary	·)			
Last Name		First Name		Middle Name	
Mendez Francicso					
Street Address 1			Street Address 2		
6317 SW 16th Street					
City		State/Province/0	Country	ZIP/Postal Code	
Miami		FLORIDA		33155	
Relationship:	Execut	ive Officer	Director	Promoter	
Relationship: Clarification of Response			Director	Promoter	

Last Name First Name Middle Name

Mendez	Yosbani
Street Address 1	Street Address 2
6317 SW 16th Street	
City	State/Province/Country ZIP/Postal Code
Miami	FLORIDA 33155
Relationship: Execut	tive Officer Director Promoter
Clarification of Response (if Necessary	y)
Former officer/director	
4. Industry Group	
Agriculture	Health Care Retailing
Banking & Financial Services	C Biotechnology C Health Insurance C Restaurants
C Commercial Banking	C Hamitala & Dhaminiana
C Insurance	Pharmaceuticals
C Investing	C Other Health Care
C Investment Banking	© Telecommunications
C Pooled Investment Fund	C Other Technology
Other Banking & Financial C Services	Travel
A.E.	C Manufacturing C Airlines & Airports
Business Services	Real Estate C Lodging & Conventions
Energy Coal Mining	C Commercial C Construction C Tourism & Travel Services
C Electric Utilities	C REITS & Finance
© Energy Conservation	C Residential C Other
C Environmental Services	Other Real Estate
C Oil & Gas	
Other Energy	
5. Issuer Size	
Revenue Range	Aggregate Net Asset Value Range
C No Revenues	C No Aggregate Net Asset Value
C \$1 - \$1,000,000	\$1 - \$5,000,000
C \$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
S5,000,001 - \$25,000,000	© \$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
Decline to Disclose	C Decline to Disclose
Not Applicable	O Not Applicable
pp.	- or opposite
Federal Exemption(apply)	(s) and Exclusion(s) Claimed (select all that
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	Rule 506(b)
Rule 504 (b)(1)(ii)	Rule 506(c)
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)

7. Type of Filing
New Notice Date of First Sale 2014-10-31 First Sale Yet to Occur
Amendment
8. Duration of Offering
Does the Issuer intend this offering to last more than one year? ${ m C}_{ m Yes}$ ${ m C}_{ m No}$
9. Type(s) of Securities Offered (select all that apply)
Pooled Investment Fund
Tenant-in-Common Securities Debt
Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Other (describe)
Security
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
Offering pursuant to Agreement and Plan of Merger between the Issuer, Nemus Acquisition Corp., Nemus and Nemus Bioscience, Inc. which closed on October 31, 2014, as described
in the Issuer's Current Report on Form 8-K on November 3,
in the Issuer's Current Report on Form 8-K on November 3, 2014.
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accented from any outside.
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside \$ 0 USD
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor USD
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient Recipient CRD Number None (Associated) Broker or Dealer None
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient Recipient CRD Number None (Associated) Broker or Dealer None
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient CRD Number None (Associated) Broker or Dealer None Number
in the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient CRD Number None (Associated) Broker or Dealer None Number
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor USD
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient CRD Number None (Associated) Broker or Dealer None Street Address 1 Street Address 2
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor USD
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor USD
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor USD
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment
In the Issuer's Current Report on Form 8-K on November 3, 2014. 11. Minimum Investment Minimum investment accepted from any outside investor 12. Sales Compensation Recipient Recipient CRD Number None (Associated) Broker or Dealer None (Associated) Broker or Dealer None Street Address 1 Street Address 2 City State/Province/Country ZIP/Postal Code State(s) of Solicitation All States

Clarification of Response (if Necessary)

Offering pursuant to Agreement and Plan of Merger between the Issuer, Nemus Acquisition Corp., Nemus and Nemus Bioscience, Inc. which closed on October 31, 2014, as described in the Issuer's Current Report on Form 8-K on November 3, 2014.

14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 0 USD
Finders' Fees \$ 0 USD Estimate
Clarification of Response (if Necessary)
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Nemus Bioscience, Inc.	/s/ John Hollister	John Hollister	Chief Executive Officer	2014-11-13